highly significantp < 0.0001
Metastases were present in 16.67% of surviving patients and 54.55% of non‐survivors, with a highly significant difference noted in the statistical analysis ( p < 0.0001).
Metastases were present in 16.67% of surviving patients and 54.55% of non‐survivors, with a highly significant difference noted in the statistical analysis ( p < 0.0001).